冠心病患者抗血小板药物的选择

被引：7

作者：

张佳慧

袁晋青

机构：

[1] 北京协和医学院中国医学科学院阜外心血管病医院心血管内科

来源：

中华临床医师杂志(电子版) | 2013年 / 7卷 / 11期

关键词：

抗血小板药物; 普拉格雷; 替格瑞洛; 氯吡格雷; 冠心病患者;

D O I：

暂无

中图分类号：

R541.4 [冠状动脉（粥样）硬化性心脏病（冠心病）];

学科分类号：

摘要：

<正>血小板活化和聚集在冠状动脉斑块破裂、血栓形成过程中发挥关键作用。因此,积极的抗血小板治疗能使冠心病患者明确获益。目前,经典的双联抗血小板治疗(氯吡格雷+阿司匹林)是预防冠状动脉介入治疗(percutaneous transluminal coronary intervention,PCI)相关及自发缺血事件的标准指南推荐疗法。新型抗血小板药物普拉格雷、替格瑞洛的出现,也为冠心病治疗提

引用

页码：4960 / 4962

页数：3

共 11 条

[1] 中国经皮冠状动脉介入治疗指南2012(简本) [J].

韩雅玲 .

中华危重症医学杂志(电子版), 2012, 5 (03) :169-180

[2] 非心脏手术患者围手术期抗血小板药物的使用 [J].

郁正亚 .

中华临床医师杂志(电子版), 2011, 5 (05) :1371-1375

[3]

Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor.[J].Estella Davis;Robyn Teply;Jon Knezevich.Clinical Pharmacology: Advances and Applications.2013, Issu

[4]

2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update).[J].Hani Jneid;Jeffrey L. Anderson;R. Scott Wright;Cynthia D. Adams;Charles R. Bridges;Donald E. Casey;Steven M. Ettinger;Francis M. Fesmire;Theodore G. Ganiats;A. Michael Lincoff;Eric D. Peterson;George J. Philippides;Pierre Theroux;Nanette K. Wenger;James Patrick Zidar.Journal of the American

[5]

Exploring the reduction in myocardial infarctions in the PLATO trial: Which patients benefited on ticagrelor vs. clopidogrel?.[J].James J. DiNicolantonio;Victor L. Serebruany.International Journal of Cardiology.2012,

[6]

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.[J].Glenn N. Levine;Eric R. Bates;James C. Blankenship;Steven R. Bailey;John A. Bittl;Bojan Cercek;Charles E. Chambers;Stephen G. Ellis;Robert A. Guyton;Steven M. Hollenberg;Umesh N. Khot;Richard A. Lange;Laura Mauri;Roxana Mehran;Issam D. Moussa;

[7] Efficacy and Safety of Intensive Antiplatelet Therapy With Prasugrel from TRITON-TIMI 38 in a Core Clinical Cohort Defined by Worldwide Regulatory Agencies [J].

Wiviott, Stephen D. ;

Desai, Nihar ;

Murphy, Sabina A. ;

Musumeci, Guiseppe ;

Ragosta, Michael ;

Antman, Elliott M. ;

Braunwald, Eugene .

AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (07) :905-911

[8] Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee Meeting Regarding Ticagrelor [J].

Gaglia, Michael A., Jr. ;

Waksman, Ron .

CIRCULATION, 2011, 123 (04) :451-456

[9] Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial [J].

Mehta, Shamir R. ;

Tanguay, Jean-Francois ;

Eikelboom, John W. ;

Jolly, Sanjit S. ;

Joyner, Campbell D. ;

Granger, Christopher B. ;

Faxon, David P. ;

Rupprecht, Hans-Jurgen ;

Budaj, Andrzej ;

Avezum, Alvaro ;

Widimsky, Petr ;

Steg, Philippe Gabriel ;

Bassand, Jean-Pierre ;

Montalescot, Gilles ;

Macaya, Carlos ;

Di Pasquale, Giuseppe ;

Niemela, Kari ;

Ajani, Andrew E. ;

White, Harvey D. ;

Chrolavicius, Susan ;

Gao, Peggy ;

Fox, Keith A. A. ;

Yusuf, Salim .

LANCET, 2010, 376 (9748) :1233-1243

[10]

Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38.[J].Stephen D. Wiviott;Eugene Braunwald;Dominick J. Angiolillo;Simha Meisel;Anthony J. Dalby;Freek W.A. Verheugt;Shaun G. Goodman;Ramon Corbalan;Drew A. Purdy;Sabina A. Murphy;Carolyn H. McCabe;Elliott M. Antman.Circulation.2008, 16

← 1 2 →